This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E75.0 (GM2 gangliosidosis) | Special Copayment Reduction: V117 (ultra-rare disease) |
| B. Synonyms | GM2 gangliosidosis type II, HEXB deficiency, hexosaminidase A·B deficiency, Hexosaminidase A and B deficiency, Total hexosaminidase deficiency, Sandhoff–Jatzkewitz disease |
| C. Adult onset | Likelihood of first onset in adulthood: present (chronic or adult form) — the acute pediatric form is most common, but a chronic·adult form presenting in adolescence or adulthood with a motor neuron disease pattern (progressive muscle weakness, muscle atrophy, seizures) has been reported with variant combinations that retain some residual HEXB activity. |
| 1. History | In 1968, Sandhoff et al. described a separate disease similar to Tay-Sachs disease but with deficiency of both hexosaminidase A·B → confirmed as caused by HEXB gene mutations → research on animal models·substrate reduction therapy in progress. |
| 2. Causes | HEXB gene variants cause β-hexosaminidase β-subunit deficiency → loss of function of both HexA (αβ) and HexB (ββ) → accumulation of GM2 ganglioside·GA2·globoside in the brain·viscera. |
| 3. Genetics | HEXB gene (5q13.3), autosomal recessive. About 30 exons. Founder variants: unlike in Jewish populations, Sandhoff disease has no ethnic predilection. Deletion of exon 1-exon 5 common in those of European descent. |
| 4. General epidemiology | About 1 per 1.3 million births (acute form). Occurs in all ethnic groups worldwide. Lower overall frequency than Tay-Sachs. Very few reports in Korea. |
| 5. Pathophysiology | Simultaneous loss of HexA·HexB → lysosomal accumulation of GM2 and GA2 → lysosomal enlargement·apoptosis in neurons → degeneration of the cortex·basal ganglia·cerebellum·spinal cord. Globoside also accumulates in the viscera (liver·spleen). |
| 6. Symptoms | Acute infantile form: developmental arrest·regression at 3–6 months, exaggerated startle response, vision loss, seizures, macrocephaly. Visceral enlargement (hepatomegaly·splenomegaly) is a point of difference from Tay-Sachs. Chronic form: progressive muscle weakness·atrophy, dysarthria. |
| 7. Signs | Fundus: cherry-red spot. Neurological: hyperreflexia·seizures·nystagmus. Hepatomegaly·splenomegaly (distinguishing from Tay-Sachs). Brain MRI: T2 hyperintensity of the basal ganglia·thalamus. EMG: denervation findings in the chronic form. |
| 8. Screening | Newborn screening: measurement of hexosaminidase A·B activity on dried blood spots (DBS) introduced in some countries. Carrier testing: serum/leukocyte HexA·B activity + HEXB gene analysis. |
| 9. Diagnosis | Confirmation: marked reduction of both HexA and HexB activity in leukocytes·serum. Identification of biallelic pathogenic HEXB variants. Differentiation from Tay-Sachs: reduction of HexA alone (Tay-Sachs) vs reduction of both HexA+B (Sandhoff). |
| 10. Treatment | No curative treatment (as of 2026). Symptomatic: anticonvulsants, nutritional support, respiratory management. Substrate reduction therapy (miglustat) and hematopoietic stem cell transplantation at the research stage. Gene therapy in preclinical development. |
| 11. Prognosis | Acute infantile form: complete developmental regression, most die at 2–5 years of age. Chronic·adult form: survival for decades possible but with progressive disability. Poor prognosis in the absence of curative treatment. |
| 12. Prevention | Genetic counseling for carrier couples. Prenatal diagnosis (chorionic villus sampling·amniocentesis + HexB activity or HEXB gene analysis). Preimplantation genetic testing (PGT) available. |
| 13. References | Sandhoff et al. 1968 and 9 other references |
Sandhoff disease was recognized as an independent disease in 1968 when the German biochemist Konrad Sandhoff and colleagues described infant patients who were clinically almost indistinguishable from Tay-Sachs disease but showed a biochemically distinct condition. Sandhoff's team found that these patients were deficient not only in β-hexosaminidase type A (HexA) but also in type B (HexB) at the same time, and they also reported that, in addition to GM2 ganglioside, GA2 (asialo-GM2) and globoside accumulate abnormally in the brain and visceral tissues. This clearly distinguished it from Tay-Sachs disease, in which only HexA (an αβ heterodimer) is deficient.
Understanding at the molecular level advanced in the 1980s. It was shown that HexA is a heterodimer composed of an α-subunit (product of the HEXA gene) and a β-subunit (product of the HEXB gene), and HexB is a homodimer composed of two β-subunits. Therefore, when a HEXB gene variant occurs, β-subunits are not produced, and both HexA and HexB lose function. This is the key molecular mechanism distinguishing it from Tay-Sachs disease, which is a deficiency of HEXA alone. In 1985, O'Brien et al. and Proia et al. cloned the HEXB gene, laying the foundation for molecular diagnosis.
In the 1990s, various animal models, including cats, dogs, and sheep, were established through natural occurrence or genetic engineering and used for pathophysiology research and evaluation of treatment strategies. In particular, a HEXB gene-deficient mouse model (Bhuvaneswaran et al., 1990s) was established, and the effects of substrate reduction therapy (SRT), hematopoietic stem cell transplantation, and viral vector-based gene therapy have been examined preclinically. Since the 2000s, SRT drugs such as miglustat (N-butyldeoxynojirimycin) have shown some effect in animal models of GM2 gangliosidosis, but there are still limitations to clinical translation.
In terms of diagnostic technology, measurement of serum·leukocyte hexosaminidase activity has been used for carrier testing and prenatal diagnosis since the 1970s–80s. Methodologies for newborn screening based on dried blood spots (DBS) have been developed at some research institutions, and since the introduction of next-generation sequencing (NGS), full analysis of the HEXB gene is becoming the standard for clinical diagnosis. In Korea, there are reports at the level of individual case reports, and it is designated as an ultra-rare disease (V117).
Sandhoff disease is a lysosomal storage disease caused by pathogenic variants in both alleles of the HEXB gene, resulting in reduced or absent synthesis of the β-subunit of β-hexosaminidase. Human lysosomal β-hexosaminidase exists as two main isoenzymes. HexA is a heterodimer (αβ) in which the α-subunit, the product of the HEXA gene, is combined with the β-subunit, the product of the HEXB gene, and HexB is a homodimer (ββ) composed of two β-subunits. When a pathogenic variant occurs in the HEXB gene, production of normal β-subunits is blocked, so both HexA and HexB lose function.
The main substrate of HexA is GM2 ganglioside, and it acts to cleave the N-acetylgalactosamine (GalNAc) residue of this glycolipid, converting it to GM3. The main substrate of HexB is globoside (Gb4Cer), which is abundant in erythrocyte membranes and renal epithelial cells. GA2 (asialo-GM2) is degraded by both enzymes. When both HexA and HexB are lost, GM2 ganglioside accumulates mainly in the lysosomes of neurons in the brain, and at the same time globoside accumulates in peripheral tissues, including the kidney, liver, spleen, and erythrocytes. This is why, unlike Tay-Sachs disease (HexA deficiency alone, no peripheral organ enlargement), visceral involvement such as hepatomegaly and splenomegaly is observed in Sandhoff disease.
The spectrum of HEXB gene variants includes point mutations (missense, nonsense), splicing variants, small insertions·deletions, and large deletions. In patients of European descent, a large deletion of about 16 kb including exons 1–5 of the HEXB gene has been reported relatively frequently. Unlike Tay-Sachs disease, Sandhoff disease has no known founder mutation with high frequency in a particular ethnicity or population, so it occurs sporadically in all ethnic groups. In combinations of mild variants that retain some residual β-subunit function, GM2 ganglioside accumulates slowly, and a chronic or adult phenotype is expressed.
The HEXB gene is located on the long arm of chromosome 5 (5q13.3) and consists of 14 exons spanning about 40 kb. The translated precursor protein is 556 amino acids, and the mature β-subunit is formed after signal peptide cleavage and processing within the lysosome. The β-subunit contains the catalytic residues of the active site (Glu355, Glu491), and the β-subunit also provides the binding domain for heterodimer formation with the α-subunit.
The mode of inheritance is autosomal recessive, and an affected child is born with a 25% probability only when two carrier (heterozygous carrier) parents have a child together. To date, more than about 50 pathogenic HEXB variants have been reported. The severe acute form is associated with large deletions, nonsense mutations, and frameshift variants, with residual enzyme activity of less than 1%. The chronic or adult form occurs with combinations of missense variants that partially preserve β-subunit structure, with residual enzyme activity at 2–10% of normal.
The three GM2 gangliosidoses (Tay-Sachs HEXA, Sandhoff HEXB, GM2A deficiency HEXOSAMINIDASE ACTIVATOR DEFICIENCY) all arise from impairment of the GM2 ganglioside degradation pathway, but their molecular causes differ. GM2A activator protein deficiency (AB variant) arises from deficiency of an auxiliary protein that the HexA enzyme needs to degrade GM2, and HexA·HexB activities themselves are normal. Therefore, the AB variant cannot be differentiated by enzyme activity testing alone, and GM2A gene analysis is needed.
In genetic counseling, carrier couples must be informed of a 25% risk of an affected child with each pregnancy, and carrier identification combines measurement of serum·leukocyte HexB activity with HEXB gene analysis. Carriers are generally characterized by a change in the HexA:HexB ratio and show enzyme activity in an intermediate range (40–60% of normal). However, because carrier determination based on enzyme activity alone may result in misclassification, molecular confirmation is recommended.
Sandhoff disease is an ultra-rare disease estimated to occur worldwide at a frequency of about 1 per 1.3 million births. In contrast to Tay-Sachs disease, which shows a high ethnically concentrated frequency of 1 per 3,900 births in Ashkenazi Jews (carrier rate 1/30), Sandhoff disease occurs sporadically in all ethnic groups and regions worldwide without particular ethnic predilection. However, in the Cree Indian (Cree-Ojibwa) Indigenous population of the province of Quebec, Canada, the carrier rate is high at about 1/14, and patients with the acute infantile form are known to be concentrated there; a high frequency of a particular HEXB variant has also been reported in some populations in Argentina.
Sandhoff disease is estimated to account for about 7–10% of all GM2 gangliosidoses (Tay-Sachs + Sandhoff + AB variant). There is no sex difference (autosomal recessive), and the proportion of new patients without a family history is considerable. There are no systematic epidemiological data on its frequency in Korea, but a small number of cases have been reported in the literature to date, and it is designated as an ultra-rare disease (Special Copayment Reduction V117). The number of patients registered in the Korean rare disease registration system is very small, making accurate calculation of prevalence difficult.
By clinical type, the acute infantile form accounts for more than 80% of all Sandhoff disease, and the subacute juvenile form and chronic·adult form are few. The chronic and adult forms have accumulated at the level of case reports, and cases have been reported in which confirmation was delayed for several years due to misdiagnosis as motor neuron disease (MND) or spinocerebellar ataxia.
In normal lysosomes, degradation of GM2 ganglioside is carried out by HexA (αβ heterodimer), with the help of the GM2A activator protein (GM2 activator protein), cleaving the terminal β-N-acetylgalactosamine (GalNAc) residue of GM2 to convert it to GM3. Both HexA and HexB are active in the acidic environment of the lysosome (pH ~4.6), and the active site structures of the two enzymes are present one each on the α-subunit and β-subunit. The active site of HexB acts mainly on neutral glycolipids such as globoside as substrates, and GM2 degradation depends mainly on HexA because of the structural property of the HexA active site (Glu323 of the α-subunit) that allows it to accommodate the anionic sulfate group of GM2.
When the β-subunit is lost due to HEXB deficiency, neither HexA (αβ) nor HexB (ββ) can be assembled and matured, so the activity of both enzymes is lost simultaneously. As a result, GM2 ganglioside cannot be degraded and accumulates within lysosomes, causing lysosomal enlargement and cellular dysfunction mainly in neurons of the brain — cortical neurons, basal ganglia neurons, cerebellar Purkinje cells, and spinal motor neurons. The accumulated GM2 promotes neuronal death through various cell injury pathways, such as lysosomal membrane damage, mitochondrial dysfunction, endoplasmic reticulum stress, and activation of apoptosis signals.
In Tay-Sachs disease, loss of HexA causes GM2 to accumulate mainly in the nervous system only, but in Sandhoff disease, loss of HexB causes globoside (Gb4Cer) to accumulate additionally in peripheral tissues such as the liver, spleen, kidney, and erythrocytes, accompanied by visceral enlargement. This is the most important clinical distinguishing criterion of Sandhoff disease. In addition, GA2 (asialo-GM2) also accumulates in the brain, aggravating neurological damage.
The core of the brain pathology is the formation of giant lysosomes (meganeurites) within neurons, observed under electron microscopy as concentric or fingerprint-like membranous cytoplasmic bodies (MCB). These bodies are structures of repeatedly stacked GM2 ganglioside bilayer membranes that disrupt intracellular signal transduction and interfere with axonal transport. Neurodegeneration begins in the cerebral cortex and spreads to the basal ganglia, cerebellum, brainstem, and spinal cord, and in this process developmental regression, seizures, vision loss, and dysphagia occur sequentially.
The clinical symptoms of Sandhoff disease are classified, according to the residual activity of the HEXB enzyme, into three main clinical types — the acute infantile form, the subacute juvenile form, and the chronic/adult form.
Acute infantile form (the most common type): development is apparently normal until 3–6 months of age, after which developmental arrest and regression begin. The earliest characteristic symptom is an exaggerated startle response, an exaggerated reaction to sudden sounds (clapping, loud noises) with increased generalized muscle tone, extension of the limbs, and facial grimacing. This response appears in the same way as in Tay-Sachs disease and occurs in response not only to auditory stimuli but also to light stimuli. Subsequently, regression of gross motor function (loss of head control, failure to sit), loss of smiling, and loss of visual fixation progress.
At 6–10 months of age, vision loss becomes evident, and a cherry-red spot is observed on fundus examination. Hearing is relatively preserved, but the response to voices decreases. Seizures (myoclonic·tonic·spasm seizures) become frequent, and dysphagia and reduced respiratory function gradually accompany. Macrocephaly arises from cerebral enlargement due to GM2 accumulation in the brain and becomes evident after several months of age.
The symptom that most clearly distinguishes Sandhoff disease from Tay-Sachs disease is visceral enlargement. Hepatomegaly and splenomegaly are observed in more than half of patients and are due to globoside accumulation in peripheral tissues. This finding can be identified from an early stage and is an important clue in the differential diagnosis of GM2 gangliosidosis in infancy.
Subacute juvenile form: begins between 3 and 10 years of age with motor incoordination, delayed or regressed language development, and behavioral changes, and progresses over several years. Neurological symptoms such as spinocerebellar ataxia and spastic paraplegia predominate, accompanied by mental decline.
Chronic·adult form: presents in late adolescence or adulthood with slowly progressive muscle weakness, muscle atrophy, seizures, dysarthria, dysphagia, lower limb spasticity, and incoordination. It can be misdiagnosed for several years because of a phenotype resembling motor neuron disease (ALS) or spinocerebellar ataxia.
The main signs that can be identified on physical examination and ancillary testing are as follows.
Fundus examination: the cherry-red spot is a finding in which GM2 accumulates in the ganglion cells of the macular retina, and against the resulting yellowish-white discolored background the fovea, with its normal vascular supply, appears red in contrast. Because this also appears in other neuronal lysosomal storage diseases such as Tay-Sachs disease, Niemann-Pick type A, and sialidosis, it is not a specific finding on its own, but it is an important diagnostic clue for GM2 gangliosidosis. After loss of the peripheral visual field, central vision is also lost, followed by optic atrophy.
Neurological signs: in the acute infantile form, hypotonia appears early and later converts to spasticity and hyperreflexia. Upper motor neuron signs such as a positive Babinski sign and clonus appear. Involuntary movements (myoclonic jerks) and generalized seizures are frequent. Nystagmus and abnormal eye movements are also observed as the disease progresses.
Hepatomegaly and splenomegaly: the most important non-neurological signs of Sandhoff disease. Because there is no visceral enlargement in Tay-Sachs disease, this finding is useful in the clinical differentiation of the two diseases. Enlargement of the liver and spleen is confirmed on abdominal palpation and quantified by ultrasound.
Brain MRI findings: early on, T2 hyperintense lesions of the basal ganglia (caudate nucleus, putamen, globus pallidus) and thalamus are characteristic. Diffuse increase in T2 signal of the cerebral cortex, followed by cerebral atrophy and white matter degeneration, progress. Cerebellar atrophy is also observed later in the disease.
Electrophysiological tests: electroencephalography (EEG) shows generalized slowing and multifocal epileptiform discharges. In the chronic·adult form, electromyography (EMG)·nerve conduction studies show denervation findings, suggesting lower motor neuron involvement.
Neuropathology: at autopsy or on brain biopsy, giant lysosomes within neurons and membranous cytoplasmic bodies (MCB) on electron microscopy are identified, findings common to GM2 gangliosidoses in general.
A standardized newborn screening program for Sandhoff disease has not yet been introduced in most countries. However, the technical feasibility has already been established, and some research institutions and countries are studying ways to include it in expanded newborn screening panels.
Dried blood spot (DBS)-based enzyme activity measurement: a method has been developed to measure β-hexosaminidase A·B activity using fluorescent substrates on DBS obtained by heel-prick blood sampling of newborns. Using a HexA-specific substrate (4-methylumbelliferyl-β-D-GlcNAc-6-sulfate, MUGS) together with a substrate for total activity including HexB (4-MU-β-D-GlcNAc, MUG) allows simultaneous screening for Tay-Sachs (HexA↓, HexB normal) and Sandhoff (both HexA·B↓). Substrate analysis based on tandem mass spectrometry (LC-MS/MS) is also under study.
Family history-based carrier testing: when there is a patient with Sandhoff disease in the family, carrier testing of siblings, parents, and relatives by measurement of serum or leukocyte HexA·B activity and HEXB gene analysis is recommended. Carriers generally have enzyme activity at 40–60% of normal. If pregnant, they are immediately referred for prenatal diagnosis.
Screening of at-risk populations: in populations with known high-frequency founder variants, such as the Canadian Cree Indians, population screening can be clinically justified. In the general population otherwise, evidence of cost-effectiveness is lacking.
Confirmation of Sandhoff disease rests on two pillars: biochemical enzyme activity measurement and HEXB gene analysis.
Enzyme activity measurement: HexA and HexB activities are measured in leukocytes or skin fibroblasts by the fluorescent substrate method. In Sandhoff disease, both HexA and HexB are markedly reduced to less than 1% of normal. In contrast, in Tay-Sachs disease only HexA is reduced and HexB is normal. Measurement is also possible in serum, but the rates of false positives·false negatives are high, so measurement in leukocytes or fibroblasts is preferred. During pregnancy, nonspecific placental hexosaminidase can confound serum results, so caution is needed.
Molecular genetic testing: pathogenic variants in both alleles are identified by Sanger sequencing of the HEXB gene or a next-generation sequencing (NGS) panel. Large deletions are detected by MLPA (multiplex ligation-dependent probe amplification). Genetic testing is used complementarily with enzyme activity measurement and is essential particularly for interpreting borderline enzyme activity results in mild·chronic forms.
Prenatal diagnosis: prenatal diagnosis is possible by measurement of HexB enzyme activity in fetal cells obtained by chorionic villus sampling (CVS, 11–14 weeks) or amniocentesis (15–20 weeks) and/or by direct detection of the HEXB variant identified in the family. Preventing implantation of affected embryos by preimplantation genetic testing (PGT-M) is also possible.
Differential diagnosis: differentiation from other lysosomal storage diseases showing a cherry-red spot and neurodegeneration is needed. Tay-Sachs disease (HEXA deficiency, HexB normal), GM2A activator deficiency (AB variant, enzyme activity normal), Niemann-Pick type A (acid sphingomyelinase deficiency), sialidosis (neuraminidase deficiency), etc. are considered.
As of 2026, there is no established disease-modifying therapy for Sandhoff disease. Treatment centers on symptomatic·supportive therapy and management of complications, and several investigational treatment strategies aimed at fundamental treatment are in progress.
Symptomatic·supportive therapy: anticonvulsants for seizure control (levetiracetam, valproic acid, clonazepam, etc.) are central. Positioning management for gastroesophageal reflux and dysphagia and feeding via nasogastric tube or gastrostomy tube are needed. When respiratory function is reduced, noninvasive positive pressure ventilation (NIV) or mechanical ventilation is considered. Oral hygiene management to prevent aspiration pneumonia and physical, occupational, and speech therapy support maintenance of function.
Substrate reduction therapy (SRT): miglustat (N-butyldeoxynojirimycin, Zavesca) is a drug that reduces substrate accumulation by inhibiting ceramide glucosyltransferase (glucosylceramide synthase), which catalyzes the first step of GM2 ganglioside synthesis. In animal models of GM2 gangliosidosis (mice), reduced brain GM2 levels and prolonged survival have been reported, but clinical trials have not yet succeeded in demonstrating a significant neuroprotective effect in humans. Evidence for clinical use is currently insufficient, but some physicians try it in situations with no alternatives.
Hematopoietic stem cell transplantation (HSCT): HSCT performed before symptoms showed some effect in animal models, but clinical results in Tay-Sachs and Sandhoff disease are very limited. It is known that once neurological involvement has progressed, transplantation cannot prevent neurodegeneration.
Enzyme replacement therapy (ERT): because of its inability to cross the blood-brain barrier (BBB), conventional intravenous ERT is limited in treating neurological involvement. Direct administration into the cerebrospinal fluid (intrathecal/intracerebroventricular ERT) is being explored at the preclinical and early clinical stages.
Gene therapy: HEXB gene delivery using AAV (adeno-associated virus) vectors has shown reduced GM2 accumulation and improved clinical symptoms in HEXB-deficient mouse and cat models and is attracting attention as the most promising research direction. Routes of direct intracerebral injection or cerebrospinal fluid administration are being explored, and phase 1/2 clinical trials are at the planning·preparation stage.
The prognosis of Sandhoff disease differs markedly by clinical type. In the acute infantile form, complete developmental regression progresses rapidly within the first 1–2 years of life, and most die at 2–5 years of age from decreased responsiveness, limb spasticity, respiratory failure, pneumonia, etc. Intensive supportive care and nutritional·respiratory management can somewhat prolong survival but do not change the fundamental course. With no curative drugs currently available, the prognosis of the acute infantile form remains poor.
In the subacute juvenile form, progressive neurological decline proceeds over 5–15 years after onset, and death often occurs in late adolescence or early adulthood. In the chronic·adult form, survival for several decades is possible, but progressive motor and cognitive decline accompany, and quality of life is greatly limited.
Factors affecting prognosis include age of onset, residual HEXB enzyme activity, degree of seizure control, and timing of respiratory complications. Early seizure control, optimization of nutrition, and prevention of aspiration help extend short-term survival. With gene therapy clinical trials under way, there are expectations for possible improvement in prognosis in the future, but clinical efficacy has not yet been established.
Prevention of Sandhoff disease focuses mainly on secondary prevention through carrier testing and prenatal·preimplantation genetic testing.
Genetic counseling: after a patient is diagnosed, the autosomal recessive mode of inheritance and the recurrence risk (25%) are fully explained to the parents, siblings, and extended family. When a carrier couple is planning a pregnancy, all options for prenatal diagnosis (chorionic villus sampling, amniocentesis, PGT-M) are offered.
Prenatal diagnosis: based on the HEXB variant identified in the family or HexB enzyme activity deficiency, fetal diagnosis is possible during pregnancy by chorionic villus sampling (11–14 weeks) or amniocentesis (15–20 weeks). A specialized genetic counseling team supports interpretation of results and decisions on pregnancy management.
Preimplantation genetic testing (PGT-M): a method of preventing pregnancy with an affected fetus altogether by selecting against affected embryos in conjunction with in vitro fertilization. It is offered as an option to carrier couples whose HEXB variants have been identified.
Population carrier testing: in populations with known high-frequency founder variants, such as the Cree Indians, carrier screening before a planned pregnancy is recommended. Universal screening of the general population is not currently recommended, but it is always recommended when there is a family history.
For primary prevention (preventing the occurrence of the disease itself), the possible application of gene editing technology at the germ cell stage is currently being studied, but because of ethical·technical limitations it has not reached the stage of clinical application.